All news

RxSight signs Alcon lens deal worth up to $200 million

Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash

RxSight announced a non-exclusive collaboration with Alcon worth up to $200 million to develop adjustable presbyopia-correcting intraocular lenses, letting the company expand beyond cataract surgery. Second-quarter product sales fell and gross margins declined. Twelve firms carry a consensus target of USD 8.17, with the next earnings report expected on November 4, 2026.

Read original source

RXST company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.